APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology

Abstract Background Apolipoprotein E ε4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD). A recent case report identified a rare variant in APOE, APOE3-R136S (Christchurch), proposed to confer resistance to autosomal dominant Alzheimer’s Disease (AD). However, i...

Descrición completa

Detalles Bibliográficos

Principais autores:	Kristine M. Tran, Nellie E. Kwang, Claire A. Butler, Angela Gomez-Arboledas, Shimako Kawauchi, Cassandra Mar, Donna Chao, Rocio A. Barahona, Celia Da Cunha, Kate I. Tsourmas, Zechuan Shi, Shuling Wang, Sherilyn Collins, Amber Walker, Kai-Xuan Shi, Joshua A. Alcantara, Jonathan Neumann, Duc M. Duong, Nicholas T. Seyfried, Andrea J. Tenner, Frank M. LaFerla, Lindsay A. Hohsfield, Vivek Swarup, Grant R. MacGregor, Kim N. Green
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2025-01-01
Series:	Molecular Neurodegeneration
Assuntos:	APOE Christchurch PS19 5xFAD Microglia DAM Amyloid
Acceso en liña:	https://doi.org/10.1186/s13024-024-00793-x
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!